ey0016.12-5 | Type 2 Diabetes | ESPEYB16
WV Tamborlane
, M Barrientos-Perez
, U Fainberg
, H Frimer-Larsen
, M Hafez
, PM Hale
, MY Jalaludin
, M Kovarenko
, I Libman
, JL Lynch
, P Rao
, N Shehadeh
, S Turan
, D Weghuber
, T Barrett
, I Ellipse Trial
N Engl J Med 2019; 10.1056/NEJMoa1903822.DOI: 10.1056/NEJMoa1903822http://www.ncbi.nlm.nih.gov/pubmed/31034184Summary: In a double-blind, randomized, phase 3 trial, 135 overweight and obese adolescents, aged 10 to 17 years with T2DM, were randomly assigned to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo, bot...